Lowenthal’s tenure as an officer and employee concluded on July 6. The company provided no specific explanation regarding his departure. Casale, who previously served as the firm’s president, brings over 25 years of experience in commercial leadership and biopharmaceutical business to the top role.
In section Market Quotes
ARS Pharmaceuticals Elevates Donn Casale to CEO
Donn Casale has assumed the role of chief executive officer at ARS Pharmaceuticals, taking the helm from co-founder Richard Lowenthal. The transition, which took effect July 7, marks a significant leadership shift for the biotechnology firm as it seeks to expand the market reach of its core neffy franchise.
Prior to his time at ARS, Casale held the position of chief commercial officer at Dynavax Technologies and managed marketing and sales operations for Depomed. Board members expressed confidence that his background will sharpen the company’s focus on long-term value creation and the ongoing commercialization of its primary product, neffy.
Comments (0)
No comments yet. Be the first!